These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
3. Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer. Zeissler ML; Li V; Parmar MKB; Carroll CB J Parkinsons Dis; 2020; 10(2):413-428. PubMed ID: 32116263 [TBL] [Abstract][Full Text] [Related]
4. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
5. Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative. Gonzalez-Robles C; Weil RS; van Wamelen D; Bartlett M; Burnell M; Clarke CS; Hu MT; Huxford B; Jha A; Lambert C; Lawton M; Mills G; Noyce A; Piccini P; Pushparatnam K; Rochester L; Siu C; Williams-Gray CH; Zeissler ML; Zetterberg H; Carroll CB; Foltynie T; Schrag A; J Parkinsons Dis; 2023; 13(6):1011-1033. PubMed ID: 37545260 [TBL] [Abstract][Full Text] [Related]
6. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial). Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D; Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924 [TBL] [Abstract][Full Text] [Related]
7. Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT. Ashburn A; Pickering R; McIntosh E; Hulbert S; Rochester L; Roberts HC; Nieuwboer A; Kunkel D; Goodwin VA; Lamb SE; Ballinger C; Seymour KC Health Technol Assess; 2019 Jul; 23(36):1-150. PubMed ID: 31339100 [TBL] [Abstract][Full Text] [Related]
8. muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Lu IN; Kulkarni S; Fisk M; Kostapanos M; Banham-Hall E; Kadyan S; Bond S; Norton S; Cope A; Galloway J; Hall F; Jayne D; Wilkinson IB; Cheriyan J Trials; 2020 Jul; 21(1):690. PubMed ID: 32736592 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
10. Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial. Kulkarni S; Fisk M; Kostapanos M; Banham-Hall E; Bond S; Hernan-Sancho E; Norton S; Cheriyan J; Cope A; Galloway J; Hall F; Jayne D; Wilkinson IB Trials; 2020 Jul; 21(1):626. PubMed ID: 32641154 [TBL] [Abstract][Full Text] [Related]
11. AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. Griffiths G; Fitzgerald R; Jaki T; Corkhill A; Marwood E; Reynolds H; Stanton L; Ewings S; Condie S; Wrixon E; Norton A; Radford M; Yeats S; Robertson J; Darby-Dowman R; Walker L; Khoo S; Trials; 2020 Jun; 21(1):544. PubMed ID: 32560744 [TBL] [Abstract][Full Text] [Related]
12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
13. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739 [TBL] [Abstract][Full Text] [Related]
14. Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. Noor NM; Pett SL; Esmail H; Crook AM; Vale CL; Sydes MR; Parmar MKB F1000Res; 2020; 9():1109. PubMed ID: 33149899 [TBL] [Abstract][Full Text] [Related]
15. ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Wilkinson T; Dixon R; Page C; Carroll M; Griffiths G; Ho LP; De Soyza A; Felton T; Lewis KE; Phekoo K; Chalmers JD; Gordon A; McGarvey L; Doherty J; Read RC; Shankar-Hari M; Martinez-Alier N; O'Kelly M; Duncan G; Walles R; Sykes J; Summers C; Singh D; Trials; 2020 Jul; 21(1):691. PubMed ID: 32736596 [TBL] [Abstract][Full Text] [Related]
16. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926 [TBL] [Abstract][Full Text] [Related]
17. Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials. Noor NM; Love SB; Isaacs T; Kaplan R; Parmar MKB; Sydes MR BMJ Open; 2022 Mar; 12(3):e055615. PubMed ID: 35273052 [TBL] [Abstract][Full Text] [Related]
18. How should we be using biomarkers in trials of disease modification in Parkinson's disease? Vijiaratnam N; Foltynie T Brain; 2023 Dec; 146(12):4845-4869. PubMed ID: 37536279 [TBL] [Abstract][Full Text] [Related]
19. Increasing Efficiency of Recruitment in Early Parkinson's Disease Trials: A Case Study Examination of the STEADY-PD III Trial. Berk S; Greco BL; Biglan K; Kopil CM; Holloway RG; Meunier C; Simuni T J Parkinsons Dis; 2017; 7(4):685-693. PubMed ID: 29103052 [TBL] [Abstract][Full Text] [Related]
20. Progress towards therapies for disease modification in Parkinson's disease. Vijiaratnam N; Simuni T; Bandmann O; Morris HR; Foltynie T Lancet Neurol; 2021 Jul; 20(7):559-572. PubMed ID: 34146514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]